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Research CCL3 and CCL20-recruited dendritic cells modified 
by melanoma antigen gene-1 induce anti-tumor 
immunity against gastric cancer ex vivo and in vivo
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Abstract
Background: To investigate whether dendritic cell (DC) precursors, recruited by injection of chemokine ligand 3 
(CCL3) and CCL20, induce anti-tumor immunity against gastric cancer induced by a DC vaccine expressing melanoma 
antigen gene-1 (MAGE-1) ex vivo and in vivo.
Methods: B6 mice were injected with CCL3 and CCL20 via the tail vein. Freshly isolated F4/80-B220-CD11c+ cells 
cultured with cytokines were analyzed by phenotype analysis and mixed lymphocyte reaction (MLR). For adenoviral 
(Ad)-mediated gene transduction, cultured F4/80-B220-CD11c+ cells were incubated with Ad-MAGE-1. Vaccination of 
stimulated DC induced T lymphocytes. The killing effect of these T cells against gastric carcinoma cells was assayed by 
MTT. INF-γ production was determined with an INF-γ ELISA kit. In the solid tumor and metastases model, DC-based 
vaccines were used for immunization after challenge with MFC cells. Tumor size, survival of mice, and number of 
pulmonary metastatic foci were used to assess the therapeutic effect of DC vaccines.
Results: F4/80-B220-CD11c+ cell numbers increased after CCL3 and CCL20 injection. Freshly isolated F4/80-B220-
CD11c+ cells cultured with cytokines were phenotyically identical to typical DC and gained the capacity to stimulate 
allogeneic T cells. These DCs were transduced with Ad-MAGE-1, which were prepared for DC vaccines expressing 
tumor antigen. T lymphocytes stimulated by DCs transduced with Ad-MAGE-1 exhibited specific killing effects on 
gastric carcinoma cells and produced high levels of INF-γ ex vivo. In vivo, tumor sizes of the experimental group were 
much smaller than both the positive control group and the negative control groups (P < 0.05). Kaplan-Meier survival 
curves showed that survival of the experimental group mice was significantly longer than the control groups (P < 0.05). 
In addition, MAGE-1-transduced DCs were also a therapeutic benefit on an established metastatic tumor, resulting in a 
tremendous decrease in the number of pulmonary metastatic foci.
Conclusions: CCL3 and CCL20-recruited DCs modified by adenovirus-trasnsduced, tumor-associated antigen, MAGE-
1, can stimulate anti-tumor immunity specific to gastric cancer ex vivo and in vivo. This system may prove to be an 
efficient strategy for anti-tumor immunotherapy.
Background
Gastric cancer is one of the most formidable cancers [1].
Although therapies have improved over the years, it is
still difficult to treat advanced gastric cancer that has
metastasized and spread to the lymph glands. Currently,
radical surgery is the only treatment with a curative
potential for this disease, and adjuvant chemotherapy or
radiotherapy have been widely applied. Nonetheless, con-
trol of gastric cancer at an advanced stage still remains
difficult [2,3]. Accordingly, new treatment modalities are
worth investment to improve 5-year survival rates of
patients. One promising approach is immunotherapy.
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Dendritic cells (DCs) are professional antigen present-
ing cells (APC) with the unique capacity to establish a
primary immune response against tumor-associated anti-
gens (T AA) [4,5]. This essential role of DCs in cellular
immunity has led to development of feasible and effective
DC-based vaccines against tumor antigens to eliminate
cancer cells. To improve the strategy for DC-based vac-
cines, it is critical to acquire a large number of appropri-
ate DCs possessing normal function. We have
demonstrated that i.v. administration of chemokine
ligand 3 (CCL3) or/and CCL20 rapidly recruits a group
of F4/80-B220-CD11c+  cells into the peripheral blood.
These cells can differentiate into mature DCs [6,7]. We
have reported previously that TAA-loaded DCs can stim-
ulate cytotoxic T lymphocytes (CTL) significantly to lyse
gastric cancer cells ex vivo [8]. Moreover, DC vaccination
induced protective immunity toward the development of
gastric cancer in vivo. However, these DC vaccines have
not been substantially effective in inducing tumor regres-
sion in established gastric cancer. Thus, their therapeutic
effects are limited. Despite this, DC-based immunother-
apy is considered promising for anti-tumor therapy.
However, new strategies for improved treatment are
necessary. Much research has focused upon finding feasi-
ble and effective DC-based vaccines. These include puls-
ing DC with tumor lysates, tumor antigen peptide, or
protein; fusing tumor cells with DC; and transducing
genes encoding tumor antigen, cytokines, or chemokines
into DCs [9]. Melanoma-associated antigen gene-1
(MAGE-1) was initially isolated from the MZ-2 human
melanoma cell line [10], which can be recognized by
CTL. We and others have previously shown that MAGE-
1 is expressed at a high frequency in gastric cancer
[11,12], which suggested MAGE-1 may be a target for
anti-tumor immunotherapy. In the present study, we
demonstrated that F4/80-B220-CD11c+  DC precursors
mobilized by CCL3 and CCL20 can induce tumor-spe-
cific CTL and elicit potent, therapeutic effects against
solid and metastatic tumors when modified with MAGE-
1. Together, our results suggest a promising new immu-
notherapeutic strategy against gastric cancer.
Methods
Animals and cell lines
Female BALB/c and C57BL/6 (B6) mice (8-10 weeks)
were purchased from the Shanghai Experimental Animal
Center, Chinese Academy of Sciences (Shanghai, China).
All mice were housed in pathogen-free conditions in the
animal center of The Medical College of Shanghai Jiao
Tong University (Shanghai, China). Animal care and use
were in compliance with institutional guidelines. Mouse
forestomach carcinoma (MFC), a mouse gastric cancer
cell line, and B16F10, a melanoma cell line of B6 (H-2b)
mouse origin were purchased from the Shanghai Cell
Biology Institutes, Chinese Academy of Sciences (Shang-
hai, China). Cells were cultured in RPMI (Roswell Park
Memorial Institute) medium 1640 (GIBCO, USA) con-
taining 12.5% fetal calf serum (FCS), penicillin G (100 U/
ml), and streptomycin (100 μg/ml) at 37°C in a humidi-
fied incubator with a 5% CO2 atmosphere.
Major reagents
Human recombinant CCL3 and CCL20 expressed in
Brevibacillus choshinensis and purified to homogeneity
was provided by Dr. Shiro Kanegasaki (Effector Cell Insti-
tute, Tokyo, Japan). Murine granulocyte-macrophage col-
ony-stimulating factor (GM-CSF), tumor necrosis factor-
α (TNFα), interleukin 4 (IL-4), IL-2, and IL-7 were pur-
chased from Becton Dickinson (New Jersey, USA). Bioti-
nylated anti-F4/80 mAb, Cy-chrome-conjugated
streptavidin, phycoerythrin (PE)-labeled anti-B220 mAb,
fluorescein isothiocyanate (FITC)-labeled anti-CD11c
mAb, rat anti-DEC-205 mAb, FITC-labeled goat anti-rat
IgG (Fab)2 antibodies, FITC-labeled mAb against CD40,
F4/80, CD11b, or CD80, and PE-labeled mAb against Ia,
CD8α, or CD86 were provided by Pharmigen (CA, USA).
Mitomycin C (MMC) was purchased from Jingmei Biothe
(Shenzhen, China).
Cell preparation
B6 mice were injected via the tail vein with 1 mg CCL3
and CCL20 in 100 μl phosphate-buffered saline (PBS) or
with the same dose PBS (control). Peripheral blood (0.8
ml per mouse) was obtained by cardiac puncture from
anesthetized mice at the indicated time intervals (0 h, 8 h,
16 h, 24 h, 48 h, 72 h, 120 h) after CCL3 and CCL20
injection. Peripheral blood mononuclear cells (PBMCs)
were prepared from peripheral blood by density separa-
tion with Ficoll. PBMCs were stained with biotinylated
anti-F4/80 mAb followed with Cy-chrome-conjugated
streptavidin, PE-labeled anti-B220 mAb, and FITC-
labeled anti-CD11c mAb for fluorescence-activated cell
sorter (FACScan, Becton Dickinson) analysis and sorting
of F4/80-B220-CD11c+ cells. Reanalysis by FACS showed
that the purity of these sorted F4/80-B220-CD11c+ cells
was greater than 98%.
DC development
DCs were generated as described previously [6,13].
Briefly, purified peripheral blood-derived F4/80-B220-
CD11c+ cells from mice injected with CCL3 and CCL20
were cultured at a concentration of 3 × 105 cells/ml in
RPMI 1640 medium containing 10% FCS, GM-CSF (4 ng/
ml), and IL-4 (10 ng/ml) for 5 d to induce their differenti-
ation into immature DCs. These were cultured further in
GM-CSF and TNFα (5 ng/ml) for 3 to 4 d to induce their
maturation. Primary DCs were obtained from mouseHe et al. Journal of Experimental & Clinical Cancer Research 2010, 29:37
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bone marrow precursors according to a previously estab-
lished protocol [13]. Mature DCs were observed by light
microscopy (Nikon, Japan).
Immunofluorescence Staining
Before and after culture with GM-CSF and IL-4 for 5 d,
and subsequent stimulation with GM-CSF and TNFα for
an additional 3 to 4 d, F4/80-B220-CD11c cells (2 × 105 to
4 × 105 cells) were incubated with rat anti-DEC-205 mAb
followed by FITC-labeled goat anti-rat IgG (Fab')2 anti-
bodies or directly with FITC-labeled mAb against CD40,
F4/80, CD11b, or CD80 and PE-labeled mAb against Ia,
CD8α, or CD86 followed by FACS analysis. The instru-
ment compensation was set in each experiment using
two-color stained samples.
Mixed Leukocyte Reaction Assay
MLR was performed in accordance with previous meth-
ods [8,14]. Immature and mature DCs were treated with
mitomycin C (MMC; 15 μg/ml) in six-well plates at 37°C
for 3 h to arrest their proliferation. After several washes
with PBS, these stimulator cells were suspended in RPMI
1640 medium containing 10% FCS at concentrations
ranging from 1 × 102 to 5 × 104 cells/ml. One hundred
microliters of the above stimulator cell suspension were
added to each well of 96-well plates that contained alloge-
neic CD4+ T cells (3 × 105 cells/100 μl per well) that had
b e e n  m a g n e t i c a l l y  i s o l a t e d  f r o m  B 6  m i c e  u s i n g  C D 4
Microbeads. Five days later, T-cell proliferation was
determined by the MTT method. Fifteen microliters of
MTT (5 μg/ml in PBS) was added to each well and the
plates were incubated at 37°C for an additional 4 h. The
resultant absorbance at 550 nm was read with a
microplate immunoreader.
Recombinant adenoviral vectors and transduction of DC
Recombinant adenovirus (Ad) encoding MAGE-1 (Ad-
MAGE-1) was donated by Dr. Yanyun Zhang (Health Sci-
ence Center of Shanghai Institute for Biological Science,
Chinese Academy of Science, China). Ad-MAGE-1 and
Ad encoding β-galactosidase (Ad-LacZ) were propagated
in 293 cells, purified on a CsCl density gradient, and their
titers determined by plaque assay on 293 cells. Aliquots of
the adenovirus solutions were stored at - 80°C for use in
the following experiments. For Ad-mediated genetic
modification,  CCL3 and CCL20-recruited DCs were
incubated with Ad-MAGE-1 or Ad-lacZ at a multiplicity
of infection (MOI) of 100 for 2 h at 37°C and then washed
twice with complete medium. The above DC vaccines are
referred to as DC-Ad-MAGE-1 and DC-Ad-lacZ, respec-
tively.  CCL3 and CCL20-recruited DCs pulsed with
freeze-thawed tumor lysates was performed in accor-
dance with previous methods [8]. The vaccine is referred
to as DC-MFC Ag.
Tumor model and DC-based vaccination
In an established tumor model, 5 × 105 MFC cells were
injected subcutaneously (s.c.) into B6 mice, and the mice
were subsequently injected s.c. with DC-Ad-MAGE-1 (1
× 106) on days 5 and 12. As controls, tumor-beating mice
were injected with DC-Ad-LacZ, DC-MFC Ag, and
untreated DC. Tumor size was evaluated every 2 to 3 d.
Survival differences among groups receiving different
vaccinations were monitored following challenge with
tumor cells. Tumor volume was estimated using the fol-
lowing formula: (short diameter)2 × long diameter × 0.52
[15]. In the pulmonary metastasis model, 5 × 105 viable
MFC tumor cells were injected into B6 mice via tail vein.
Mice with pulmonary metastasis were innoculated into
the tail vein (i.v.) with 1 × 106 DC-Ad-MAGE-1 in tripli-
cate at days 3, 7 and 11 after tumor cell injection, respec-
tively. Tumor metastases were evaluated by counting the
number of metastases in the lungs of killed mice in mac-
rography.
CTL assay and interferon gamma (IFN-γ) secretion
Splenic CD3+ T cells (1 × 106 cells/ml) were cultured in
RPMI 1640 containing 10% FCS, then primed ex vivo in
the presence of cytokines including IL-2 and IL-7 (5 ng/
ml, each) at days 0, 7, and 14 with DC-Ad-MAGE-1 at a
stimulator-to-responder cell ratio of 1:20. At day 21 the
primed T cells as effector cells were added into 96 well
plates containing target MFC or B16F10 tumor cells by
serial target cell dilutions (E-T mix, E: T 1:1, 5:1, 10:1,
25:1, 50:1, 100:1). After 20 h, supernatant from each well
was collected for measuring cytolytic activity against tar-
get cells with a Cytotoxicity Detection Kit (Boehringer
Mannheim, Mannheim, Germany). In some experiments,
CD3+ T cells were isolated from tumor-free mice that sur-
vived for 60 d after tumor cell challenge. These T cells (1
× 106  cells/ml) were restimulated ex vivo with 1 ×
105MMC-treated MFC tumor cells, which were collected
for measuring CTL activity and IFN- γ secretion five days
later.
Statistical analysis
Differences were evaluated using Statistical Package for
Social Science 11.5 (SPSS 11.5). Survival differences
among groups of mice were evaluated with a long-rank
test of the Kaplan-Meier survival curves. Statistical tests
were two-sided. P values < 0.05 were considered to be sta-
tistically significant.
Results
Identification of CCL3 and CCL20-recruited DC
The amounts of F4/80-B220-CD11c+ cells recruited into
the peripheral blood were investigated at different time
intervals following CCL3 and CCL20 injection. The
results showed that numbers of F4/80-B220-CD11c+ cellsHe et al. Journal of Experimental & Clinical Cancer Research 2010, 29:37
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gradually increased while there was no change in PBS-
injected mice. The percentage of F4/80-B220-CD11c+
cells reached their highest level (16.55 ± 1.32% of PBMCs)
approximately 48 h after CCL3 and CCL20 injection
(Fig. 1).
The CCL3 and CCL20-recruited F4/80-B220-CD11c+
c e l l s  w e r e  n e x t  e x a m i n e d  b y  m o r p h o l o g y ,  p h e n o t y p e
analysis, and MLR. Cells were compared morphologically
before and after culturing with GM-CSF, IL-4, and TNFα.
Light microscopy showed that culturing with cytokines
resulted in large cells with oval or irregularly shaped
nuclei and many small dendrites (Fig. 2, compare panel
B to panel A). Phenotypically, FACS analysis showed that
fresh (i.e., uncultured) F4/80-B220-CD11c+  cells
expressed moderate levels of CD40; low levels of Ia,
CD80, CD86, and DEC-205 molecules; and were negative
for F4/80 and CD8α antigen (Fig. 3). Functionally, these
cells were unable to stimulate allogeneic T cells in a MLR
assay (Fig. 4). By contrast, cultured F4/80-B220-CD11c+
cells expressed high levels of Ia, CD86, CD80, and DEC-
205 antigen (Fig. 3) and acquired the capacity to enhance
allogeneic T cell proliferation as effectively as mature,
BM-derived DCs (Fig. 4).
Generation of tumor-specific CTL induced byDC-Ad-MAGE-
1 ex vivo
To study the potential of CCL3 and CCL20-recruited
DCs in anti-tumor immunity ex vivo, DC-MAGE-1 were
employed after five days of culture with GM-CSF and IL-
4. Splenic T cells from naïve mice were primed ex vivo
with DC-Ad-MAGE-1 in the presence of IL-2 and IL-7 to
elicit cytolytic reactivity against tumor cells. When T
cells primed with DC-Ad-MAGE-1 were added to tumor
cells, they were able to efficiently and specifically lyse
MFC, but not B16F10 tumor cells, which do not express
MAGE-1. The results also showed that T cells primed
with DC-Ad-LacZ or untreated DC did not induce spe-
cific CTL (Fig. 5). The results of CTL responses ex vivo
suggested that vaccination with MAGE-1-modified DC
may prove useful for anti-tumor immunotherapy in vivo.
A therapeutic effect mediated by DC-Ad-MAGE-1 in vivo
Therapeutic potential of DC-Ad-MAGE-1 was further
explored with an established tumor model. 5 × 105 MFC
or B16F10 tumor cells were implanted s.c in B6 mice, and
tumor-bearing mice were injected with different modi-
fied or unmodified DCs on days 5 and 12. Fig. 6A shows
that tumor growth was significantly inhibited in mice
vaccinated with DC-Ad-MAGE-1. For example, tumor
volumes on day 27 were as follows: untreated DC control
Figure 1 CCL3 and CCL20 injection recruites F4/80-B220-CD11c+ 
cells into the peripheral blood in mice. B6 mice were injected via the 
tail vein with 1 mg of CCL3 and CCL20 or with PBS (control). Peripheral 
blood was obtained by cardiac puncture at the different time intervals 
(0 h, 8 h, 16 h, 24 h, 48 h, 72 h, 120 h). F4/80-B220-CD11c+ cells were 
sorted from PBMNCs and analyzed by FACS. Results are given as means 
± SD with 10 mice per group from three independent experiments.
Figure 2 Morphological characteristics of CCL3 and CCL20-re-
cruited F4/80-B220-CD11c+ cells before and after culture. (A), Fresh 
CCL3 and CCL20-recruited F4/80-B220-CD11c+ cells were sorted from 
PBMNCs of mice by FACS and observed by light microscopy (original 
magnification ×200). (B), These cells were cultured with GM-CSF and 
TNFα for 5~6 days, then were observed by light microscopy (Giemsa 
staining was performed, original magnification ×400).He et al. Journal of Experimental & Clinical Cancer Research 2010, 29:37
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14.98 ± 1.81 cm3, DC-Ad-LacZ control 15.44 ± 1.99 cm3,
DC-MFC Ag control 7.79 ± 1.55 cm3, DC-Ad-MAGE-1
3.46 ± 1.12 cm3, DC-Ad-MAGE-1 vs. the other control
groups (P < 0.05). Half of the tumor-bearing mice immu-
nized with DC-Ad-MAGE-1 survived in a period of over
60 days. By contrast, only 10% of the tumor-bearing mice
immunized with DC-MFC Ag survived; all mice from the
other control groups succumbed to growing tumors
within 25 days, thus providing no therapeutic effect (Fig.
6B). The differences between the DC-Ad-MAGE-1 group
and all control groups were statistically significant (P <
0.05).
To confirm that tumor-specific CTLs had indeed been
generated in the immunized mice, the following evalua-
tion was performed. Spleen T cells from mice immunized
s.c with DC-Ad-MAGE-1, and thus rendered tumor-free
after MFC tumor challenge, were restimulated ex vivo
with irradiated tumor cells and tested for cytolytic activ-
ity. As shown in Fig. 7A, these effector cells efficiently
lysed MFC, but not B16F10 tumor cells. Control spleen T
cells from naive mice stimulated with irradiated MFC
tumor cells failed to demonstrate CTL activity. Further-
more, splenic CD3+ T cells derived from those mice that
survived MFC challenge produced high levels of IFN-γ,
but not when stimulated with B16F10 cells (Fig. 7B). This
observation indicates that the vaccination effect of DCs
expressing the tumor antigen gene is antigen specific.
Finally, administration of DC-Ad-MAGE-1 was tested
as a possible therapeutic benefit for distant, established
visceral metastases. In this treatment model, the benefit
of CCL3 and CCL20-recruited DCs as a tumor treat-
ment was quantified by counting metastatic foci in pul-
monary tumor-bearing mice. These were established by
i.v. administration of 5 × 105 viable MFC tumor cells.
M e t a s t a t i c  l u n g  t u m o r s  w e r e  o b s e r v e d  a t  d a y  3  a f t e r
tumor cell implantation. Subsequently, tumor-bearing
Figure 3 Immunophenotypic analysis of CCL3 and CCL20-recruit-
ed F4/80-B220-CD11c+ cells. CCL3 and CCL20-recruited F4/80-B220-
CD11c+ cells cultured for 5~8 days were incubated with PE or FITC-la-
beled MAbs. The phenotype of these cells was analyzed by immuno-
fluorescence staining as described in the Materials and Methods. 
Results are given as means ± SD from three independent experiments.
Figure 4 The capacity of CCL3 and CCL20-recruited F4/80- B220-
CD11c+ cells to enhance allogeneic MLR. Allogeneic MLR were per-
formed using splenic T cells purified from B6 mice as responder cells. 
Fresh and cultured F4/80-B220-CD11c+ cells were treated with MMC to 
arrest cell proliferation and were used as stimulator cells at the indicat-
ed cell numbers, respectively. Macrophage were used as controls. T 
cell proliferation was determined with MTT after 5 days of culture. Re-
sults are expressed as the mean ± SD of triplicate cultures. All data are 
representative of three independent experiments.
Figure 5 Generation of tumor-specific CTLs ex vivo. Splenic CD3+ T 
cells were isolated from B6 mice with MACS. T cells were primed with 
MAGE-1-modified DCs as described in Materials and Methods. DC-Ad-
LacZ and untreated DCs were used as controls. Primed T cells (effector 
cells) were titrated by serial dilution, then mixed with MFC or B16F10 
target cells, and their lytic activity was assayed. Results are given as 
means ± SD from three independent experiments.He et al. Journal of Experimental & Clinical Cancer Research 2010, 29:37
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mice were treated with 1 × 106 DC-Ad-MAGE-1 cells in
triplicate at days 3, 7 and 11 after injection of tumor cells.
As controls, mice were treated to the same regimen with
either DC-Ad-LacZ, DC-MFC Ag, or untreated DCs. Vis-
ible lung metastases in these mice were counted in mac-
rography at day 21 after tumor cell inoculation. Mice
treated with DC-Ad-MAGE-1 showed a dramatic reduc-
tion in the number of lung metastatic foci. However, a
decrease did not appear in mice receiving the control
treatments (Table 1).
Figure 6 Inhibition of tumor growth in tumor-bearing mice by 
immunization with MAGE-1-modified, CCL3 and CCL20-recruited 
DC vaccine. (A), Each of 10 mice in a group was challenged s.c. with 1 
× 105 viable MFC tumor cells. Mice were subsequently injected s.c. with 
DC-Ad-MAGE-1 5 days later. As controls, tumor-bearing mice were in-
jected with DC-Ad-LacZ, DC-MFC Ag, or untreated DCs. Survival was 
observed over time after immunization of mice harboring preexisting 
tumors. Survival rate was compared with a long-rank test of Kaplan-
Meier curves. (B), Tumor growth was measured every 2~3 days after 
the second immunization. Data are given as means ± SD of 10 mice per 
group from three independent experiments.
Figure 7 Assay for tumor-specific, CTL activity and IFN-γ secre-
tion in immunized mice. (A), Splenic T cells from immunized mice 
were restimulated ex vivo by culturing with MMC-treated, MFC tumor 
cells. The restimulated T cells (effector cells) were incubated with tar-
get MFC or B16F10 cells for 20 h. Cytolytic activity (lysis) was deter-
mined. (B), Supernatants were collected for IFN-γ assay. All data are 
shown as means ± SD for 10 mice per group and are representative of 
three independent experiments. * P < 0.05.
Table 1: Treatment of distant metastatic tumors with 
MAGE-1-modified DC vaccines
Treatment Number of Lung 
metastases
DC-Ad-MAGE-1 *31.38 ± 2.26
DC-Ad-LacZ 120.75 ± 2.71
DC-MFC Ag 77.25 ± 3.37
Untreated DC 124.38 ± 3.58
* P < 0.05, DC-Ad-MAGE-1 versus the other control groups.He et al. Journal of Experimental & Clinical Cancer Research 2010, 29:37
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Discussion
We have demonstrated that after injection of CCL3 and
CCL20, F4/80-B220-CD11c+ DC precursors are quickly
recruited into the peripheral blood. Furthermore, these
CCL3 and CCL20-recruited DCs, when modified with
tumor antigen gene MAGE-1, could induce not only an
effective CTL response against gastric cancer cells ex vivo
but also therapeutic, anti-tumor immunity in both subcu-
taneous tumor and pulmonary metastatic tumor models.
Among many different immunotherapeutic strategies
currently being evaluated, DC-based vaccination has
attracted particular attention as a proven safe and potent
therapy against tumors [14,16]. Induction of tumor
immunity can be initiated by effectors of innate immunity
and can be further developed by cells of adaptive immu-
nity, with DCs playing a central regulatory role. Several
steps are involved including (a) recognition of tumor
molecules by DC precursors, (b) direct and IFN-γ-medi-
ated killing of transformed cells by NK/NK T cells acti-
vated by DCs, (c) capture and cross presentation of
released TAA by immature DCs, (d) selection and activa-
tion of TAA-specific T cells, as well as nonspecific effec-
tors including macrophages and eosinophils, and (e)
homing of TAA-specific T cells to the tumor site and rec-
ognition leading to elimination of tumor cells [16]. DC-
based vaccination had presented efficient anti-tumor
activity in numerous tumor models and in clinical stud-
ies. Kono K [17] reported that vaccines using DCs pulsed
with HER-2/neu-peptides may represent a novel treat-
ment of gastric cancer patients.
DC migration in vivo involves three steps: mobilization
into the blood, recruitment from blood to peripheral tis-
sues, and remobilization from peripheral to lymphoid tis-
sues. Once there, immature DCs finally differentiate into
fully mature DCs to promote immune responses.
Although the first step has not received much attention, it
is important to understand how this step is regulated in
order to understand the pathologic role of DCs in various
inflammatory diseases and in tumor development.
Chemokines selectively direct the trafficking of subsets of
leukocytes into various tissues in homeostasis as well as
inflammatory states in vivo [18]. The capacity of DCs to
migrate to sites of inflammation, where they capture anti-
gens and subsequently migrate to local lymph nodes, is
regulated by the expression of different chemokines and
chemokine receptors [19,20].
Mobilization of DCs and DC precursors into peripheral
blood is of particular interest in research related to DC-
based immunotherapy. We have demonstrated that
murine F4/80-B220-CD11c+  DC precursors rapidly
appear in peripheral blood when animals are injected i.v.
with CCL3 and CCL20 [7]. These F4/80-B220-CD11c+
cells subsequently differentiate into mature DCs when
cultured ex vivo with GM-CSF and TNFα. The resultant
DCs present the typical morphological characteristics,
phenotypes, and antigen-presenting functions of DCs (as
assessed in MLR assays). Because injections of CCL3
and CCL20 did not induce any detectable inflamma-
tory response or liver injury in vivo (data not shown),
we believe it is possible that CCL3 and CCL20 could
be employed to efficiently recruit DC precursors for
the purpose of DC-based cancer therapy.
There are two considerably important factors involved
in DC-based vaccination in the clinic: one is the way to
effectively and practically obtain abundant DCs in
peripheral blood; the other is a method to effectively
m o d i fy  DC s  u s e d  a s  v a c c i n e s  f o r  t u m o r  r e j e c t i o n  a n d
therapy [21]. Successful genetic modification of murine
CCL3 and CCL20-recruited DCs with adenoviral vectors
was demonstrated. Adenovrial-based gene therapy has
many advantages over other forms of TAA delivery [22].
Adenoviral vectors allow local, highly efficient, albeit
transient, gene expression, generating high-level, but lim-
ited, cytokine production in treated tumors. Adenoviral
vectors are transduction agents in a heterogeneously
growing population of tumor cells. In this study, murine
DCs were transduced using cocultivation with adenoviral
vectors. The murine CCL3 and CCL20 -recruited DCs
were transduced with MAGE-1 at different MOI and dif-
ferent time intervals in culture. DCs transduced with
MAGE-1 at an MOI of 100 showed limited toxicity and
maximal production of MAGE-1 (data not shown).
In this study, CCL3 and CCL20-recruited DCs were
modified with a tumor antigen gene and used as vaccines
for an anti-tumor immune response ex vivo and in vivo.
Ex vivo, when T cells were primed with MAGE-1-modi-
fied DCs and added to tumor cells, they were able to lyse
tumor cells efficiently and specifically. High cytolytic
activity in association with a Th1-type response could
possibly contribute to the profound anti-tumor effects
that we observed. In vivo, vaccination with CCL3 and
CCL20-recruited DCs modified with MAGE-1 remark-
ably inhibited subcutaneous tumor growth and size. This
observation suggests the treatment potential of these
cells as vaccines. In addition, splenic T cells obtained
from mice vaccinated with DC-Ad-MAGE-1 produced
high levels of IFN-γ and showed specific cytotoxic activ-
ity. By contrast, responses induced by nontransduced
DCs and TAA-loaded DCs were far less potent. While
most DC-based vaccination strategies target solid,
non-metastatic tumors, our vaccination strategy
employing TAA gene-modified DCs revealed efficacy
against metastatic tumors as well. Future work will
address the idea that this approach may be a viable
one for treatment of gastric cancers in patients.He et al. Journal of Experimental & Clinical Cancer Research 2010, 29:37
http://www.jeccr.com/content/29/1/37
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Conclusion
In this study, we demonstrated that F4/80-B220-CD11c+
DC precursors were rapidly recruited into the peripheral
blood by administration of CCL3 and CCL20 in mice.
This is essential for preparing DC-based vaccines against
tumors. Importantly, vaccination with these DCs modi-
fied with MAGE-1, could elicit specific CTL responses to
gastric cancer cells, and led to tumor rejection ex vivo
and in vivo. These results suggest that an evaluation of
this DC-based immunotherapy strategy for gastric cancer
patients is an important next step.
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